Altered Peptide Ligand NBI-6024 Failed to Protect Insulin-Making Cells in New Type 1 Diabetes

What the researchers found

NBI-6024, an altered peptide ligand designed to inhibit autoreactive T-cells, failed to preserve beta-cell function in newly diagnosed type 1 diabetes patients across all three doses tested.

Mean peak C-peptide concentrations at 24 months were nearly identical across groups: 0.59 pmol/ml (0.1 mg), 0.57 pmol/ml (0.5 mg), 0.48 pmol/ml (1.0 mg), and 0.54 pmol/ml (placebo). C-peptide levels declined by approximately 60% over 24 months in all groups. Daily insulin needs at month 24 were comparable between groups. No treatment-related changes in islet antibodies or T-cell numbers were observed, suggesting the peptide failed to modulate the immune response as intended.

Why it matters

Type 1 diabetes affects millions worldwide, and finding a way to stop the immune system from destroying insulin-producing cells early in the disease could be transformative. While this trial was negative, it provided important data about the altered peptide ligand approach and helped guide future immune-modulation strategies for type 1 diabetes prevention.

How the study worked

This was a randomized, placebo-controlled, dose-ranging phase 2 trial. A total of 188 patients aged 10-35 with recently diagnosed type 1 diabetes were randomly assigned to receive subcutaneous injections of placebo or NBI-6024 at 0.1, 0.5, or 1.0 mg. Injections were given at baseline, weeks 2 and 4, then monthly for 24 months. Beta-cell function was measured every 3 months using C-peptide concentrations during a 2-hour mixed-meal tolerance test. Immune markers including islet antibodies and T-cell counts were also tracked.

What this study cannot tell us

The study may have enrolled patients too late in the disease process for immune modulation to work, as significant beta-cell destruction may have already occurred by the time of diagnosis. The peptide may not have been potent enough to overcome the established autoimmune process. The age range of 10-35 years is broad, and younger patients may respond differently to immune modulation than adults.

How to read the evidence

This is a well-designed randomized, placebo-controlled, dose-ranging phase 2 trial with 188 patients and 24 months of follow-up. It represents moderate-to-high quality clinical evidence, though the negative result means it demonstrates what doesn't work rather than what does.

When this study was published

Published in 2009, this trial informed the direction of subsequent type 1 diabetes immunotherapy research. The altered peptide ligand approach has largely been superseded by newer immune-modulation strategies, though the lessons from this trial remain relevant.

The bigger picture

This negative trial is part of a broader search for immune-modulating peptides that could halt or slow type 1 diabetes progression. While NBI-6024 failed, the field has continued exploring other peptide-based immune therapies, including tolerogenic approaches and combination strategies. Negative results like these are crucial for steering research away from ineffective approaches.

Questions still open

• Would earlier intervention with immune-modulating peptides — before clinical type 1 diabetes onset — show better results?
• Did NBI-6024 fail because of the peptide approach itself, or because this specific peptide wasn't potent enough?
• Could combination therapy with other immunomodulators have enhanced NBI-6024's effect on autoreactive T-cells?

Common questions

Read the original research

No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes.

Diabetes care, 32(11), 2036-40

Citation

Walter, Markus; Philotheou, Areti; Bonnici, François; Ziegler, Anette-G; Jimenez, Roland. (2009). No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes.. Diabetes care, 32(11), 2036-40. https://doi.org/10.2337/dc09-0449